ICL for Myopia

Implantable collamer lenses (ICLs) are phakic intraocular lenses used to correct myopia and, in some designs, myopic astigmatism while preserving the natural crystalline lens. They are positioned as an alternative to corneal refractive procedures for selected adults, particularly where corneal thickness, ocular-surface symptoms, refractive error, or patient preference make laser-based correction less suitable. Clinical decision-making depends on stable refraction, anterior-segment anatomy, endothelial-cell status, lens design, surgeon expertise, and long-term follow-up.

The field is being shaped by broader recognition that refractive correction should be personalized rather than procedure-led. Advances in lens sizing, central-flow designs, imaging, and toric alignment support more individualized treatment planning, while preoperative screening increasingly emphasizes anterior-chamber depth, angle anatomy, endothelial health, retinal status, and realistic expectations. At the same time, informed consent is placing greater weight on possible enhancement, rotation, removal, cataract development, pressure-related complications, glare, halos, and the need for lifelong monitoring.

Artificial intelligence is increasingly relevant to the diagnostic and operational layers of ICL care, although clinical validation and clinician oversight remain essential. Machine-learning tools can assist with biometry quality control, anterior-segment image interpretation, vault assessment, toric-axis planning, and identification of inconsistent measurements. AI may also help standardize postoperative documentation and flag patients requiring review. Its practical value depends on representative training data, transparent performance testing, cybersecurity, privacy compliance, and clear accountability when algorithmic recommendations conflict with clinical judgment.

North America is characterized by advanced refractive-surgery infrastructure, stringent device oversight, and high demand for elective vision correction, with access influenced by out-of-pocket payment. Latin America combines experienced ophthalmic centers with uneven affordability, referral pathways, and regulatory access across countries. Europe benefits from established specialist networks and harmonized-but not identical-regulatory and reimbursement environments. The Middle East includes concentrated investment in private ophthalmology and medical tourism alongside differing national approval and payment systems. Africa remains diverse, with access constrained in many areas by specialist availability, equipment, follow-up capacity, and affordability. Asia-Pacific contains major ophthalmology hubs and substantial unmet refractive needs, but varies widely in regulation, training, purchasing power, and rural access.

ASEAN markets require approaches that account for varied regulatory systems, healthcare financing, and concentrations of specialist care. BRICS countries span large and contrasting populations, manufacturing capabilities, clinical ecosystems, and access conditions, making group-level assumptions unreliable. The European Union offers cross-border regulatory alignment through shared frameworks, while clinical practice and reimbursement remain nationally differentiated. G7 economies generally provide mature specialist services, sophisticated diagnostics, and strong safety-monitoring expectations, but elective payment models can limit access. GCC countries combine high private-sector capacity with regional referral activity, whereas NATO members represent a diverse set of health systems rather than a single commercial or clinical market.

Australia and Canada combine established ophthalmic services with geographically dispersed populations. Brazil and Mexico have substantial private ophthalmology capacity but face affordability and regional-access differences. China and India offer large patient pools, expanding specialist networks, and pronounced variation between metropolitan and nonmetropolitan care. France, Germany, Italy, Spain, and the United Kingdom operate within mature European clinical environments, with differences in payment, referral, regulation, and elective-care pathways. Japan and South Korea are technologically advanced markets with strong specialist expertise and distinct demographic and regulatory contexts. Russia’s access environment is shaped by domestic health-system conditions, specialist distribution, and device availability. The United States has extensive refractive expertise and advanced diagnostics, while coverage is commonly influenced by elective-care economics and provider-level purchasing decisions.

Industry leaders should prioritize evidence generation that follows patients over the long term and reports clinically meaningful outcomes, including vault behavior, endothelial-cell changes, pressure events, visual symptoms, explantation, and cataract-related outcomes. Standardized patient-selection protocols and measurement-quality controls can reduce avoidable variability. Training should address sizing, toric alignment, complication management, and shared decision-making. Organizations should also build transparent post-market surveillance, support independent clinical education, and evaluate access models that improve affordability without weakening follow-up. AI investments should begin with narrowly defined, auditable use cases and retain clinician responsibility for final decisions.

This summary uses a structured review framework focused on the clinical role, technology evolution, safety considerations, regulatory context, and access conditions associated with ICL treatment for myopia. Evidence assessment should prioritize peer-reviewed clinical studies, regulatory documents, professional guidance, prospective registries, and institutional outcomes, while distinguishing randomized evidence from observational findings and expert opinion. Geographic comparisons should be interpreted qualitatively because diagnostic capacity, reporting practices, reimbursement, patient selection, and follow-up duration differ substantially. No market estimates, market shares, forecasts, or company-specific claims are used.

ICLs occupy an important position in the refractive-correction pathway for appropriately selected patients with myopia, especially when corneal laser treatment is unsuitable or less preferred. The field’s progress will depend less on procedure availability alone than on rigorous screening, accurate sizing, skilled implantation, durable follow-up, transparent safety reporting, and informed patient choice. Regional and country conditions will continue to shape access, while carefully validated digital and AI tools may improve consistency without replacing specialist judgment.